Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GPRC5D CAR-T in relapsed/refractory multiple myeloma
NCT05739188Phase 2Recruiting
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CT071 in multiple myeloma (MM). Started Feb 2023; status: recruiting.
02
Drugs
CT071
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05739188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739188.